European Union - English - EMA (European Medicines Agency)

navidea biopharmaceuticals europe ltd. - tilmanocept - radionuclide imaging - tumour detection, diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.radiolabelled lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.external imaging and intraoperative evaluation may be performed using a gamma detection device.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - mometasone furoate - cutaneous cream - 1mg/1gram

European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - docetaxel - stomach neoplasms; adenoma; breast neoplasms; carcinoma, non-small-cell lung; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancerdocetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinomadocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancerdocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - nebivolol hydrochloride - oral tablet - 10mg

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - olmesartan medoxomil - film coated tablet - 10 milligram - angiotensin ii antagonists, plain - angiotensin ii antagonists - treatment of essential hypertension in adults and treatment of hypertension in children and adolescents from 6 to less than 18 years of age

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - olmesartan medoxomil - film coated tablet - 20 milligram - angiotensin ii antagonists, plain - angiotensin ii antagonists - treatment of essential hypertension in adults and treatment of hypertension in children and adolescents from 6 to less than 18 years of age

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - olmesartan medoxomil - film coated tablet - 40 milligram - angiotensin ii antagonists, plain - angiotensin ii antagonists - treatment of essential hypertension in adults and treatment of hypertension in children and adolescents from 6 to less than 18 years of age.

United Kingdom - English - myHealthbox

glenmark pharmaceuticals europe limited - olmesartan medoxomil - film-coated tablets - 10mg - angiotensin ii antagonists - treatment of essential hypertension in adults. treatment of hypertension in children and adolescents from 6 to less than 18 years of age.

United Kingdom - English - myHealthbox

glenmark pharmaceuticals europe limited - olmesartan medoxomil - film-coated tablets - 20mg - angiotensin ii antagonists - treatment of essential hypertension in adults. treatment of hypertension in children and adolescents from 6 to less than 18 years of age.